Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 21, 2026
BOK Financial Corporation (BOKF) Shares Q2 2026 Earnings Update

BOK Financial Corporation (BOKF) Shares Q2 2026 Earnings Update

Key Takeaways

  • BOK Financial Corporation reported operating results for the second quarter ended June 30, 2026, on July 20, 2026.
  • The company hosted a conference call to review the financial results at noon central time on July 21, 2026.
  • Full earnings details are available via the company's investor relations website.
  • BOK Financial manages approximately $53 billion in assets and $129 billion in assets under management or administration.
  • The regional bank operates across multiple states with a focus on commercial and consumer banking services.
  • Investors are monitoring the detailed metrics from the official release for performance trends.

Why This Quarter Matters

BOK Financial Corporation's quarterly results offer a useful window into how a sizable regional bank is navigating shifting interest rates and broader economic conditions. With roughly $53 billion in assets and operations across eight states, the company's performance in lending, deposit gathering, and fee-based services can highlight trends that matter to the sector as a whole. Earlier quarters have demonstrated steady execution in core areas, so this second-quarter update serves as a timely checkpoint for evaluating profitability and balance-sheet strength.

What the Release Shows

BOKF released its second-quarter 2026 operating results on July 20, 2026. The announcement points investors to the full earnings materials for detailed figures on revenue, earnings per share, and other operating metrics. Management will discuss those results in the conference call scheduled for July 21. Specific comparisons to analyst estimates and prior periods appear in the official documents posted on the investor relations site. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Market Reaction So Far

Following the July 20 release, investors are examining the reported numbers to assess how BOKF performed relative to expectations. The timing of the announcement and the follow-up conference call has drawn attention from those focused on regional banking dynamics. Sentiment will likely be influenced by the detailed metrics in the full release and any commentary from management during the call.

Forward Outlook and Areas to Monitor

Attention now turns to what the second-quarter results imply for BOKF's full-year path. Any guidance offered during the earnings call should provide additional clarity on net interest income trends and loan growth in the current rate environment. Key items to watch include deposit cost pressures, credit quality metrics, and growth in fee income from wealth management and trust services. The company's multi-state footprint may also reveal regional economic differences affecting commercial and consumer lending demand. Additional catalysts could include updates on capital deployment, potential acquisitions, or regulatory changes affecting regional banks. Tracking balance-sheet composition and margin performance will help gauge resilience amid industry-wide challenges.

Using AI Tools in My Research Process

When analyzing earnings releases like this one, I often turn to Tickeron’s AI Screener to quickly filter banking stocks by fundamentals, technical patterns, and performance metrics. It helps surface comparable names and highlight any standout characteristics without spending hours on manual screening. The tool is available at AI Screener and has become a regular part of my workflow for sector comparisons.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BOKF

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


Momentum Indicator for BOKF turns positive, indicating new upward trend

BOKF saw its Momentum Indicator move above the 0 level on July 31, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BOKF advanced for three days, in of 300 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 201 cases where BOKF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 55 cases where BOKF's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for BOKF turned negative on August 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BOKF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BOKF broke above its upper Bollinger Band on August 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 55, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BOKF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.447) is normal, around the industry mean (1.352). P/E Ratio (13.650) is within average values for comparable stocks, (24.299). BOKF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.846). Dividend Yield (0.017) settles around the average of (0.031) among similar stocks. P/S Ratio (4.027) is also within normal values, averaging (3.855).

Notable companies

The most notable companies in this group are PNC Financial Services Group (NYSE:PNC), US Bancorp (NYSE:USB), Itau Unibanco Banco Holding SA (NYSE:ITUB), Deutsche Bank Aktiengesellschaft (NYSE:DB), Huntington Bancshares (NASDAQ:HBAN), Banco Bradesco SA (NYSE:BBD), Regions Financial Corp (NYSE:RF), KeyCorp (NYSE:KEY).

Industry description

Regional banks have a smaller reach than major banks, and cater mostly to one region of a country, such as a state or within a group of states. They offer services often similar – albeit with some limitations/smaller scale – compared to major banks. Taking deposits, making loans, mortgages, leases, credit cards , fund management, insurance and investment banking. SunTrust Banks, State Street Corp., M&T Bank Corp. are some examples of U.S. regional banks.

Market Cap

The average market capitalization across the Regional Banks Industry is 6.5B. The market cap for tickers in the group ranges from 10.73K to 142.82B. CIHHF holds the highest valuation in this group at 142.82B. The lowest valued company is ACBCQ at 10.73K.

High and low price notable news

The average weekly price growth across all stocks in the Regional Banks Industry was -0%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 12%. CCB experienced the highest price growth at 12%, while NEWT experienced the biggest fall at -15%.

Volume

The average weekly volume growth across all stocks in the Regional Banks Industry was 11%. For the same stocks of the Industry, the average monthly volume growth was -5% and the average quarterly volume growth was -31%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 52
Price Growth Rating: 47
SMR Rating: 53
Profit Risk Rating: 55
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
BOKF
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a regional bank

Industry RegionalBanks

Profile
Details
Industry
Regional Banks
Address
Boston Avenue at Second Street
Phone
+1 918 588-6000
Employees
5034
Web
https://www.bokf.com
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ÂĄ1.81 trillion, up 3.7% YoY, on track for its full-year target of ÂĄ2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.